No such message found

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: AE/LFT concerns
2
Nov 16, 2019 05:37PM
8
bfw
Nov 16, 2019 05:39PM
7
Nov 16, 2019 05:42PM

45 more patients discontinued, that’s 65% more than placebo and nearly 4% of participants. Why is that not significant?

I don’t think we can be so dismissive of >5x elevations. Not a clinician but the math seems like a larger absolute number of patients would experience liver issues than would avoid cardiac events.

For patients who discontinued, how do we know it was transient? 

6
Nov 16, 2019 06:56PM
3
Nov 16, 2019 07:54PM
2
Nov 16, 2019 08:51PM
Share
New Message
Please login to post a reply